BrightFocus-Funded Research Shows Parkinson’s Drug Could be Repurposed to Save Sight of Millions
In a major scientific breakthrough, a drug used to treat Parkinson’s and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans.
The findings, published in the American Journal of Medicine, are a groundbreaking effort in the fight against age-related macular degeneration (AMD), which affects as many as 11 million Americans. AMD hinders central vision, and even when it does not lead to blindness it can severely reduce the ability to read, drive, and recognize faces.
In the study, supported in part by BrightFocus Foundation, researchers discovered a biological connection between darker pigmented eyes, that are known to be resistant to AMD, and increased levels of a chemical called L-DOPA in those eyes. Since L-DOPA is frequently prescribed for Parkinson’s patients, the researchers wanted to know whether patients who received the drug L-DOPA as treatment for Parkinson’s or other diseases were protected from AMD. By combing through massive databases of medical chart data, they reported that patients receiving L-DOPA were significantly less likely to get AMD, and when they did, its onset was significantly delayed.
“Rather than looking at what might cause AMD, we instead wondered why certain people are protected from AMD. This approach had never been done before,” says senior author Brian McKay of the University of Arizona.
The research findings are based off an analysis of the medical records of 37,000 patients at the Marshfield Clinic in Wisconsin. Because the average age of those given L-DOPA is 67, while the average age of AMD diagnosis is 71, scientists were able to effectively track patterns. These major findings were then confirmed by reviewing a data set of 87 million patients. In this large scale data set, L-DOPA also delayed or prevented AMD from progressing to its “wet” form, the most devastating form of the disease.
“This exciting breakthrough shows the power of scientific discovery to give hope to millions of people across the nation and the world. Their methodology is a reminder that ‘big data’ is not a buzzword—it is a bold and innovative new approach to science,” said BrightFocus president and CEO Stacy Pagos Haller.
The Latest on: L-DOPA
via Google News
The Latest on: L-DOPA
- Michael J. Fox Opens Up About Recent Health Scares and Parkinson's Disease Battle on March 1, 2019 at 9:16 pm
"I still believe in a cure," he expresses. "For so long, Sinemet L-dopa [a brand-name version of the carbidopa-levodopa medication used to treat Parkinson’s symptoms] was the gold standard. That was a... […]
- L-Dopa for Parkinson’s on February 12, 2019 at 9:30 pm
The standard symptomatic therapy for PD for more than 30 years has been levodopa. Levodopa works by replacing the chemical messenger dopamine, which the brain cells in the substantia nigra are no long... […]
- L-Dopa and Parkinsonism. on February 8, 2019 at 5:44 pm
Eighty papers (with discussions) from a symposium held in Val David, Quebec, 9 to 11 November 1969, forming a thorough review of recent and current studies in biochemistry, physiology, pharmacology, a... […]
- Good News, Bad News on Levodopa for Parkinson's Disease on January 23, 2019 at 2:33 pm
Doctors often delay prescribing levodopa, or L-dopa, to Parkinson's patients for fear that the drug might have toxic effects that produce jerky involuntary body movements over time. But patients start... […]
- UMass Amherst Plant Researcher Studies Faba Bean, a Natural Source of L-DOPA Used by Parkinson’s Patients on July 9, 2018 at 10:05 am
AMHERST, Mass. – In a new study, plant scientist Fatemeh Etemadi at the University of Massachusetts Amherst’s Stockbridge School of Agriculture, who promotes faba bean as a cold-hardy crop that can th... […]
- Modification of Parkinsonism — Chronic Treatment with L-Dopa on April 23, 2018 at 12:14 pm
Slowly increasing oral doses of L-3,4-dihydroxyphenylalanine (L-dopa) induced at least partial improvement of some manifestations in a series of 28 patients with Parkinsonism. Improvement of performan... […]
- Swede, 2 Americans Win Nobel for Brain Study / Research helped lead to drugs Prozac, L-dopa on March 5, 2018 at 2:41 pm
Two Americans and a Swede whose research explained how memory works and laid the foundation for the development of Prozac, other antidepressants and L-dopa, the most widely used Parkinson's drug, have ... […]
- Inhibition of mTOR Signaling in Parkinson’s Disease Prevents l-DOPA–Induced Dyskinesia on March 3, 2018 at 4:00 pm
1 Department of Neuroscience, Karolinska Institutet, Retzius väg 8, 171 77 Stockholm, Sweden. 2 Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021, USA. ... […]
- Cortical markers of L-DOPA-induced dyskinesias on January 14, 2018 at 4:00 pm
Parkinson’s disease (PD) is a neurodegenerative disorder that affects about 1% of the population over 55. After more than 50 years, dopaminergic treatment is still the gold standard in PD therapy, alt... […]
- Dyskinesia: L-Dopa-Induced and Tardive Dyskinesia on October 3, 2017 at 5:00 pm
Neuroleptic induced tardive dyskinesia and L-dopa-induced dyskinesia are the two most common types of drug-induced abnormal involuntary movements. These two drug-induced dyskinesias are clearly differ... […]
via Bing News